Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 22 | 2019 | 501 | 1.840 |
Why?
|
| Magnetic Resonance Imaging | 25 | 2019 | 2262 | 1.650 |
Why?
|
| Prostate | 13 | 2019 | 124 | 1.030 |
Why?
|
| Breast Neoplasms | 5 | 2019 | 1233 | 0.880 |
Why?
|
| Mammography | 3 | 2017 | 294 | 0.870 |
Why?
|
| Breast | 2 | 2017 | 194 | 0.840 |
Why?
|
| Image Enhancement | 10 | 2014 | 193 | 0.630 |
Why?
|
| Contrast Media | 9 | 2017 | 432 | 0.600 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 22 | 0.520 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 24 | 0.510 |
Why?
|
| Image Interpretation, Computer-Assisted | 6 | 2014 | 188 | 0.440 |
Why?
|
| Magnetite Nanoparticles | 1 | 2015 | 29 | 0.440 |
Why?
|
| Pattern Recognition, Automated | 7 | 2019 | 52 | 0.410 |
Why?
|
| Polymers | 1 | 2015 | 332 | 0.350 |
Why?
|
| Neoplasm Staging | 6 | 2015 | 552 | 0.320 |
Why?
|
| Brachytherapy | 2 | 2013 | 40 | 0.280 |
Why?
|
| Biopsy, Needle | 3 | 2015 | 133 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2015 | 704 | 0.240 |
Why?
|
| Sensitivity and Specificity | 10 | 2019 | 1172 | 0.240 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 1116 | 0.230 |
Why?
|
| Image-Guided Biopsy | 3 | 2015 | 50 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 1662 | 0.220 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2017 | 300 | 0.200 |
Why?
|
| Elasticity | 2 | 2015 | 46 | 0.190 |
Why?
|
| Humans | 31 | 2019 | 65646 | 0.190 |
Why?
|
| Male | 25 | 2019 | 31295 | 0.180 |
Why?
|
| Middle Aged | 14 | 2019 | 18439 | 0.160 |
Why?
|
| Algorithms | 7 | 2014 | 1052 | 0.150 |
Why?
|
| Colonic Polyps | 2 | 2010 | 25 | 0.150 |
Why?
|
| Radiometry | 1 | 2019 | 39 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 273 | 0.140 |
Why?
|
| Colon | 2 | 2010 | 148 | 0.140 |
Why?
|
| Subtraction Technique | 2 | 2008 | 24 | 0.140 |
Why?
|
| Gadolinium DTPA | 3 | 2010 | 84 | 0.130 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2017 | 11 | 0.130 |
Why?
|
| Breast Density | 1 | 2017 | 17 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2017 | 76 | 0.130 |
Why?
|
| Rectum | 4 | 2013 | 97 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2019 | 6948 | 0.120 |
Why?
|
| Aged | 11 | 2017 | 15089 | 0.120 |
Why?
|
| Reproducibility of Results | 8 | 2014 | 1715 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 113 | 0.120 |
Why?
|
| Phantoms, Imaging | 2 | 2015 | 239 | 0.120 |
Why?
|
| Phospholipases A2 | 1 | 2015 | 15 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 173 | 0.110 |
Why?
|
| Poultry | 1 | 2015 | 9 | 0.110 |
Why?
|
| Ultrasonography, Mammary | 1 | 2015 | 19 | 0.110 |
Why?
|
| Surgical Instruments | 1 | 2015 | 44 | 0.110 |
Why?
|
| Cytosol | 1 | 2015 | 184 | 0.110 |
Why?
|
| Female | 8 | 2019 | 34309 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 72 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2015 | 71 | 0.110 |
Why?
|
| Optical Imaging | 1 | 2015 | 77 | 0.110 |
Why?
|
| Cattle | 1 | 2015 | 320 | 0.110 |
Why?
|
| Atlases as Topic | 1 | 2014 | 14 | 0.110 |
Why?
|
| Principal Component Analysis | 2 | 2014 | 65 | 0.100 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 204 | 0.100 |
Why?
|
| Air | 2 | 2010 | 16 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2014 | 166 | 0.100 |
Why?
|
| Biopsy | 1 | 2015 | 460 | 0.100 |
Why?
|
| Genomics | 1 | 2016 | 386 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2012 | 3329 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 124 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 289 | 0.090 |
Why?
|
| Rectal Diseases | 1 | 2010 | 29 | 0.080 |
Why?
|
| Liver | 1 | 2015 | 874 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2015 | 491 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2496 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 367 | 0.070 |
Why?
|
| Support Vector Machine | 2 | 2019 | 25 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 278 | 0.070 |
Why?
|
| Barium Sulfate | 1 | 2007 | 17 | 0.060 |
Why?
|
| Time Factors | 1 | 2015 | 3777 | 0.060 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 88 | 0.060 |
Why?
|
| Adult | 7 | 2019 | 17511 | 0.060 |
Why?
|
| Kinetics | 1 | 2008 | 757 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 797 | 0.050 |
Why?
|
| Seminal Vesicles | 1 | 2004 | 8 | 0.050 |
Why?
|
| ROC Curve | 2 | 2019 | 294 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 216 | 0.050 |
Why?
|
| Urethra | 1 | 2004 | 77 | 0.050 |
Why?
|
| Prostatectomy | 2 | 2014 | 104 | 0.050 |
Why?
|
| Tomography, Spiral Computed | 1 | 2002 | 22 | 0.040 |
Why?
|
| Endosonography | 1 | 2002 | 27 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 526 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 213 | 0.040 |
Why?
|
| Interatrial Block | 1 | 2019 | 2 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2019 | 20 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 764 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 67 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 39 | 0.040 |
Why?
|
| Animals | 2 | 2015 | 21465 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 42 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 102 | 0.030 |
Why?
|
| Iopamidol | 1 | 2017 | 13 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2017 | 11 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 5656 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2016 | 2113 | 0.030 |
Why?
|
| Acridines | 1 | 2015 | 2 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2015 | 38 | 0.030 |
Why?
|
| Enzyme Assays | 1 | 2015 | 13 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 132 | 0.030 |
Why?
|
| Probability | 1 | 2015 | 170 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 992 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 197 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2013 | 41 | 0.020 |
Why?
|
| Boston | 1 | 2013 | 260 | 0.020 |
Why?
|
| Machine Learning | 1 | 2014 | 196 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1573 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2011 | 19 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 405 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 160 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 149 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 216 | 0.020 |
Why?
|
| Choline Kinase | 1 | 2008 | 1 | 0.020 |
Why?
|
| Neuropeptide Y | 1 | 2008 | 13 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1453 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2008 | 53 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 36 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 5820 | 0.020 |
Why?
|
| Swine | 1 | 2008 | 397 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 344 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 234 | 0.020 |
Why?
|
| Fluorocarbons | 1 | 2007 | 54 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 588 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1581 | 0.010 |
Why?
|
| Biomarkers | 1 | 2004 | 1487 | 0.010 |
Why?
|